About
Lynx Dx develops MyProstateScore 2.0, a urine-based diagnostic test analyzing 18 gene transcripts and optional clinical risk factors to assess the risk of clinically significant prostate cancer, aiding physician decision-making.
Explore Lynx Dx's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.